WO2003072090A3 - Use of tyrosine kinase inhibitors for treating cns disorders - Google Patents

Use of tyrosine kinase inhibitors for treating cns disorders Download PDF

Info

Publication number
WO2003072090A3
WO2003072090A3 PCT/IB2003/001425 IB0301425W WO03072090A3 WO 2003072090 A3 WO2003072090 A3 WO 2003072090A3 IB 0301425 W IB0301425 W IB 0301425W WO 03072090 A3 WO03072090 A3 WO 03072090A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
cns disorders
treating cns
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/001425
Other languages
French (fr)
Other versions
WO2003072090A2 (en
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03712535A priority Critical patent/EP1478380B1/en
Priority to US10/505,842 priority patent/US20050222091A1/en
Priority to AU2003216625A priority patent/AU2003216625A1/en
Priority to DE60307237T priority patent/DE60307237T2/en
Priority to CA002477111A priority patent/CA2477111A1/en
Priority to JP2003570836A priority patent/JP2005526048A/en
Priority to SI200330427T priority patent/SI1478380T1/en
Application filed by AB Science SA filed Critical AB Science SA
Publication of WO2003072090A2 publication Critical patent/WO2003072090A2/en
Publication of WO2003072090A3 publication Critical patent/WO2003072090A3/en
Anticipated expiration legal-status Critical
Priority to CY20061101257T priority patent/CY1105577T1/en
Priority to US12/191,149 priority patent/US20090082360A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a method for treating CNS disorders, more particularly selected from the group consisting of depression, schizophrenia, anxiety, migraine, memory loss, pain and neurodegenerative diseases, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
PCT/IB2003/001425 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders Ceased WO2003072090A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/505,842 US20050222091A1 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders
AU2003216625A AU2003216625A1 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders
DE60307237T DE60307237T2 (en) 2002-02-27 2003-02-26 USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CNS DISEASES
CA002477111A CA2477111A1 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders
JP2003570836A JP2005526048A (en) 2002-02-27 2003-02-26 Methods of using tyrosine kinase inhibitors for treating CNS diseases
EP03712535A EP1478380B1 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders
SI200330427T SI1478380T1 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders
CY20061101257T CY1105577T1 (en) 2002-02-27 2006-09-04 USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CNS DISORDERS
US12/191,149 US20090082360A1 (en) 2002-02-27 2008-08-13 Use of tyrosine kinase inhibitors for treating CNS disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35965202P 2002-02-27 2002-02-27
US60/359,652 2002-02-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/191,149 Division US20090082360A1 (en) 2002-02-27 2008-08-13 Use of tyrosine kinase inhibitors for treating CNS disorders

Publications (2)

Publication Number Publication Date
WO2003072090A2 WO2003072090A2 (en) 2003-09-04
WO2003072090A3 true WO2003072090A3 (en) 2003-11-13

Family

ID=27766120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/001425 Ceased WO2003072090A2 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating cns disorders

Country Status (12)

Country Link
US (2) US20050222091A1 (en)
EP (1) EP1478380B1 (en)
JP (1) JP2005526048A (en)
AT (1) ATE334693T1 (en)
AU (1) AU2003216625A1 (en)
CA (1) CA2477111A1 (en)
CY (1) CY1105577T1 (en)
DE (1) DE60307237T2 (en)
DK (1) DK1478380T3 (en)
ES (1) ES2269994T3 (en)
PT (1) PT1478380E (en)
WO (1) WO2003072090A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1434991B1 (en) * 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
PT1401416E (en) * 2001-06-29 2007-02-28 Ab Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
CA2452169A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2003035050A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
US20060128720A1 (en) * 2002-03-21 2006-06-15 Kufe Donald W Inhibition of cell death responses induced by oxidative stress
PL1684750T3 (en) 2003-10-23 2010-10-29 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
WO2005102318A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
CN103342701B (en) 2007-02-13 2016-09-21 Ab科学有限公司 Thiazolamine compound polymorphic as inhibitors of kinases and preparation method thereof
WO2008121346A1 (en) * 2007-03-30 2008-10-09 Massachusetts Institute Of Technology Methods for identifying compounds that modulate neurotrophic factor signaling
WO2008145789A1 (en) * 2007-05-28 2008-12-04 Pontificia Universidad Catolica De Chile Use of compounds derived from benzamidine methanesulphonate or a pharmaceutically acceptable salt thereof, for example imatinib mesylate, for the preparation of a drug for the treatment of neurodegenerative niemann-pick c disease (npc)
EP2068152A1 (en) * 2007-12-06 2009-06-10 Max-Delbrück-Centrum für Molekulare Medizin (MDC) c-Kit as a novel target for the treatment of pain
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
CN113272308B (en) 2018-11-20 2025-03-18 乔治敦大学 Compositions and methods for treating neurodegenerative, myodegenerative and lysosomal storage disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
WO1999061028A1 (en) * 1998-05-27 1999-12-02 Gorbach Sherwood L Isoflavonoids for treatment and prevention of migraine headaches

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558653A (en) * 1968-05-20 1971-01-26 Searle & Co Dialkylaminoalkyl-indolines
US3725403A (en) * 1970-10-20 1973-04-03 Squibb & Sons Inc Benzothiazine derivatives
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
JP5004392B2 (en) * 1999-12-22 2012-08-22 スージェン， インク． Method for regulating c-kit tyrosine protein kinase function using indolinone compounds
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
SK287335B6 (en) * 2000-10-27 2010-07-07 Novartis Ag Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin- 3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for the preparation of pharmaceutical compositions for the treatment of gastrointestinal stromal tumours
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
CA2452169A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452390A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
EP1471907B1 (en) * 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
EP1434991B1 (en) * 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
US7700610B2 (en) * 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
PT1401416E (en) * 2001-06-29 2007-02-28 Ab Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
EP1401414A2 (en) * 2001-06-29 2004-03-31 AB Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
US20050054617A1 (en) * 2001-06-29 2005-03-10 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2005507916A (en) * 2001-09-20 2005-03-24 アブ サイエンス Use of potent, selective and non-toxic c-kit inhibitors for the treatment of bacterial infections
JP2005511596A (en) * 2001-09-20 2005-04-28 アブ サイエンス Methods of using tyrosine kinase inhibitors for whitening human skin and treating diseases associated with melanocyte dysfunction
WO2003035050A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
EP1469810A4 (en) * 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO AMYLOID-BETA PEPTIDE
US20050089838A1 (en) * 2002-06-28 2005-04-28 Alain Moussy Method for identifying compounds that specifically deplete mast cells
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
WO1999061028A1 (en) * 1998-05-27 1999-12-02 Gorbach Sherwood L Isoflavonoids for treatment and prevention of migraine headaches

Also Published As

Publication number Publication date
ES2269994T3 (en) 2007-04-01
US20090082360A1 (en) 2009-03-26
EP1478380A2 (en) 2004-11-24
DE60307237T2 (en) 2007-10-18
PT1478380E (en) 2006-12-29
DK1478380T3 (en) 2006-11-27
AU2003216625A1 (en) 2003-09-09
CA2477111A1 (en) 2003-09-04
ATE334693T1 (en) 2006-08-15
EP1478380B1 (en) 2006-08-02
WO2003072090A2 (en) 2003-09-04
JP2005526048A (en) 2005-09-02
US20050222091A1 (en) 2005-10-06
DE60307237D1 (en) 2006-09-14
CY1105577T1 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
WO2003002114A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
DK1478380T3 (en) Use of tyrosine kinase inhibitors to treat CNS disorders
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003002107A3 (en) Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
WO2003002108A3 (en) Use of tyrosine kinase inhibitors for treating inflammatory diseases
DK1401413T3 (en) Use of tyrosine kinase inhibitors for the treatment of allergic diseases
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
ATE401079T1 (en) THE USE OF C-KITE INHIBITORS TO TREAT AUTOIMMUNE DISEASES
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
WO2003002105A3 (en) Use of tyrosine kinase inhibitors for treating bone loss
MXPA05013224A (en) Pyridinyl carbamates as hormone-sensitive lipase inhibitors.
WO2003004007A3 (en) Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
MXPA05001277A (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors.
WO2005016323A3 (en) Use of c-kit inhibitors for treating type ii diabetes
WO2003004006A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2003035049A3 (en) Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
WO2001097810A3 (en) Use of therapeutic benzamide derivatives
WO2003028711A3 (en) Use of c-kit inhibitors for the treatment of myeloma
MA28279A1 (en) INDOLE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS, IN PARTICULAR IKK2 INHIBITORS
WO2004096225A3 (en) Use of tyrosine kinase inhibitors for treating cerebral ischemia
WO2003035050A3 (en) Use of tyrosine kinase inhibitors for promoting hair growth
WO2005102346A3 (en) Use of c-kit inhibitors for treating fibrosis
WO2003072106A3 (en) Use of tyrosine kinase inhibitors for treating substance use disorders
WO2002051848A3 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2477111

Country of ref document: CA

Ref document number: 2003216625

Country of ref document: AU

Ref document number: 2003570836

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003712535

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003712535

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10505842

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003712535

Country of ref document: EP